Abstract:The D1 dopamine receptor is linked to a variety of neuropsychiatric disorders and represents an attractive drug target for the enhancement of cognition in schizophrenia, Alzheimer disease, and other disorders. Positive allosteric modulators (PAMs), with their potential for greater selectivity and larger therapeutic windows, may represent a viable drug development strategy, as orthosteric D1 receptor agonists possess known clinical liabilities. We discovered two structurally distinct D1 receptor PAMs, MLS6585 and MLS1082, via a high-throughput screen of the NIH Molecular Libraries program small-molecule library. Both compounds potentiate dopamine-stimulated G protein- and β-arrestin-mediated signaling and increase the affinity of dopamine for the D1 receptor with low micromolar potencies. Neither compound displayed any intrinsic agonist activity. Both compounds were also found to potentiate the efficacy of partial agonists. We tested maximally effective concentrations of each PAM in combination to determine if the compounds might act at separate or similar sites. In combination, MLS1082 + MLS6585 produced an additive potentiation of dopamine potency beyond that caused by either PAM alone for both β-arrestin recruitment and cAMP accumulation, suggesting diverse sites of action. In addition, MLS6585, but not MLS1082, had additive activity with the previously described D1 receptor PAM "Compound B," suggesting that MLS1082 and Compound B may share a common binding site. A point mutation (R130Q) in the D1 receptor was found to abrogate MLS1082 activity without affecting that of MLS6585, suggesting this residue may be involved in the binding/activity of MLS1082 but not that of MLS6585. Together, MLS1082 and MLS6585 may serve as important tool compounds for the characterization of diverse allosteric sites on the D1 receptor as well as the development of optimized lead compounds for therapeutic use.

Colocalization Strategy Unveils an Underside Binding Site in the Transmembrane Domain of Smoothened Receptor

Effect of Mutations on Drug Resistance of Smoothened Receptor Toward Inhibitors Probed by Molecular Modeling

Crystal Structure of a Multi-Domain Human Smoothened Receptor in Complex with a Super Stabilizing Ligand

Solubilization, purification, and ligand binding characterization of G protein-coupled receptor SMO in native membrane bilayer using styrene maleic acid copolymer

Small Molecule Antagonists in Distinct Binding Modes Inhibit Drug-Resistant Mutant of Smoothened.

Converse Conformational Control of Smoothened Activity by Structurally Related Small Molecules

Molecular Insights into Ago-Allosteric Modulation of the Human Glucagon-Like Peptide-1 Receptor

Integrative residue-intuitive machine learning and MD Approach to Unveil Allosteric Site and Mechanism for β2AR

Exploring an Intracellular Allosteric Site of CC-Chemokine Receptor 4 from 3D Models, Probe Simulations, and Mutagenesis

Computational elucidation of allosteric communication in proteins for allosteric drug design

Discovery of cryptic allosteric sites using reversed allosteric communication by a combined computational and experimental strategy

One-Step Synthesis and Oriented Immobilization of Strep-Tag II Fused PDGFRβ for Screening Intracellular Domain-Targeted Ligands

Allosteric nanobodies to study the interactions between SOS1 and RAS

In silico mapping of allosteric ligand binding sites in type-1 cannabinoid receptor

Structure of the human smoothened receptor bound to an antitumour agent

Highly sensitive detection of Smoothened based on the drug binding and rolling cycle amplification

Intracellular Binding Site for a Positive Allosteric Modulator of the Dopamine D1 Receptor

Importance of protein flexibility in molecular recognition: a case study on Type-I1/2 inhibitors of ALK.

Molecular mechanism of allosteric modulation for the cannabinoid receptor CB1

Binding Position Dependent Modulation of Smoothened Activity by Cyclopamine

Computational insights into diverse binding modes of the allosteric modulator and their regulation on dopamine D1 receptor